PYC Therapeutics financials at a glance

+ Portfolio

The revenue of PYC Therapeutics is reported as 0.01591 billion Dollars in the fiscal year 2023. The earnings were -0.01 Dollars per share in 2023, which was 100 higher than 2014. And about -0.02491 billion Dollars are reported as free cash flow in the financials of PYC Therapeutics 2023. No dividends were paid to the shareholders of the PYC Therapeutics stock ASX:PYC in the financial year 2023.

$15.91M

Revenue

$-0.01

Earnings Per Share

100.00%

Gross Margin %

$-24.91M

Free Cash Flow

Revenue

15.91

Earnings Per Share

-0.01

Gross Margin %

100.00

Free Cash Flow

-24.91

Financials

Year	Year	TTM	2023	2014	2013	2012	2011	2010
Rev.	Revenue	N/A	$15.91M	$0.70M	$0.71M	$1.92M	$2.36M	$0.60M
GM %	Gross Margin %	100.00%	100.00%	0.00%	0.00%	-58.58%	-28.84%	0.00%
OM	Operating Margin	-,148.24%	-,148.24%	0.00%	0.00%	-,211.95%	-,157.63%	0.00%
EPS	Earnings Per Share	$-0.01	$-0.01	$-0.00	$-0.01	$-0.01	$-0.01	$-0.02
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	-0.00%	-0.00%	-0.00%	0
Sha.	Shares	N/AM	3,732.87M	1,002.07M	466.89M	466.89M	405.2M	235.75M
OCF	Operating Cash Flow	N/A	$-24.42M	$0.00M	$0.00M	$0.00M	$0.00M	$-3.63M
FCF	Free Cash Flow	N/A	$-24.91M	$0.00M	$0.00M	$0.00M	$0.00M	$-3.79M
FCFS	Free Cash Flow Per Share	$-0.01	$-0.01	$-0.00	$-0.01	$-0.01	$-0.01	$-0.02

PYC Therapeutics financials at a glance

Financials

Discover